Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Cost of Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cost of Revenue for 15 consecutive years, with -$13.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 254.86% to -$13.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.6 million, a 47.51% decrease, with the full-year FY2025 number at $11.6 million, down 60.66% from a year prior.
  • Cost of Revenue was -$13.5 million for Q4 2025 at Niagen Bioscience, down from $20.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $20.1 million in Q3 2025 to a low of -$13.5 million in Q4 2025.
  • A 5-year average of $6.2 million and a median of $6.8 million in 2021 define the central range for Cost of Revenue.
  • Biggest YoY gain for Cost of Revenue was 483.77% in 2025; the steepest drop was 388.08% in 2025.
  • Niagen Bioscience's Cost of Revenue stood at $9.3 million in 2021, then fell by 13.4% to $8.0 million in 2022, then soared by 35.75% to $10.9 million in 2023, then fell by 20.14% to $8.7 million in 2024, then plummeted by 254.86% to -$13.5 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cost of Revenue are -$13.5 million (Q4 2025), $20.1 million (Q3 2025), and -$6.1 million (Q2 2025).